News | May 05, 2023
India is emerging as a favourable destination to conduct clinical trials: PwC-USAIC Report
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Pheezee is designed to assess musculoskeletal and neuromuscular health.
Organ Transplants triple across the country; rise from 5000 (2013) to more than 15000 in 2022
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Subscribe To Our Newsletter & Stay Updated
